Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q4 FY2011 Earnings Presentation
30 slides from Alembic Pharmaceuticals's earnings presentation, March 2011
Slide 1: Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited
Slide 2: Safe Harbour Statement
SAFE HARBOUR STATEMENT Materials and information provided during this presentation may contain ‘forward- looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to dif
Slide 3: Presentation Structure
PRESENTATION STRUCTURE • Background • Growth Drivers • Infrastructure • Strategy and Business Units * Branded Formulations * International Business * Research & Development • Financials
Slide 4: Philosophy: Vision and Mission
PHILOSOPHY Vision To become a knowledge driven global pharmaceutical company with the highest levels of operational excellence in all the spheres Mission Alembic’s mission is to grow as a Company that stands for the highest level of quality standards, innovations, customer services and commitment in
Slide 5: About Alembic
ABOUT ALEMBIC • Established in 1907 • Leaders in the Macrolides segment • Leading Brands- Althrocin, Azithral, Wikoryl, Roxid, Zeet, Ulgel, Strox • Rapid Internationalisation
Slide 6: Growth Drivers
GROWTH DRIVERS • Retaining and consolidating strong presence in acute therapies in the domestic market • Growing chronic therapies through multiple marketing divisions • Partner in the international market through alliances with big pharma and leading generics companies • Contract development and ma
Slide 7: Infrastructure
INFRASTRUCTURE Research & Development (Alembic Research Center) • Fully equipped R&D centre at Vadodara with over 270 scientists • 90 bed Bio-study centre at Vadodara • State of the art analytical instrumentation support like NMR, XRD, TGA, DSC, LCMS Formulations – Generics (Regulatory Markets) • US
Slide 8: Infrastructure
INFRASTRUCTURE Branded Formulations–Semi Regulated Markets • Formulations plant at Baddi, Himachal Pradesh • Direct presence in 30 countries API • USFDA, EDQM, TGA, WHO approved API facility at Panelav (two units) and at Karkhadi IPR • Regulatory capabilities to file across the globe
Slide 9: Business Model
BUSINESS MODEL DOMESTIC GLOBAL DOSAGE PHARMACEUTICALS API FORMS/SPECIALITY (BRANDED GENERICS) PRODUCTS India centric Business Contract Manufacturing Based on Technology, Strengths in Macrolides Synergistic with licensing, & product (40%- Indian Market share) Pharmaceutical business development 12th
Slide 10: Branded Formulations
BRANDED FORMULATIONS
Slide 11: Formulations
FORMULATIONS • Strong presence in anti-infective, pain management, cough and cold, GI therapeutic groups • Thrust on Cardiology, Gynecology, Diabetes, Orthopedics / rheumatology and Ophthalmology segments • Focus on specialty segments like ENT, Pediatrics, General Physicians, Geriatrics, Gynecology
Slide 12: Formulations: Market Presence
FORMULATIONS Market Presence • Field Force of more than 3000 people. • Ranked 20th* in the Indian formulations market with a market share of 1.78%. • Ranked 15th ** in Doctors prescription universe. • Improved performance in chronic segment through increased prescription from cardiologist, diabetolo
Slide 13: ORG Rank of Top Brands
(ORG RANK OF TOP BRANDS) Brands Rank MAR’11 Azithral 19 Althrocin 36 Roxid 79 Wikoryl 132 Zeet 287
Slide 14: International Business
INTERNATIONAL BUSINESS
Slide 15: International Business
INTERNATIONAL BUSINESS • Alembic partners Multinational and Innovator Companies for Contract manufacturing • Alliances with leading generic players in USA, Europe, Canada, Australia and South Africa • End-to-end integration in Macrolides • Create a robust product basket with 10-12 DMFs & 15- 20 ANDA
Slide 16: International Business: Generic Alliances
INTERNATIONAL BUSINESS Generic Alliances • Preferred Supply Chain Partner for Alliances. • Revenues streams through: • Sale of APIs • Supply chain partnership with big pharma and leading generic companies for formulations • Formulation Development • Customs Synthesis
Slide 17: Transformation
R & D ANDA’S TRANSFORMATION Objective Challenges Strategy Action To be a vertically •Changing •Capabilities & •Increase international Landscape due to Technology DMF/ANDA filing player in the consolidation •Product Portfolio •DP: Capacity & generic space •Price Pressure •Move up value FDA approval •
Slide 18: Key Drivers
KEY DRIVERS • Venlafaxine – Drug substance to XR drug product • Azithromycin / Azithromycin Monohydrate and salts & intermediates • Pramipexole and value added formulations • Contract development and manufacturing for big pharma and leading generic companies. • Creating basket of NDDS products and o
Slide 19: R&D ANDAs
R & D ANDA’S 60 53 50 38 ANDA filings 40 15 approvals in place 38 30 28 20 19 15 9 10 10 8 11 8 3 0 3 0 0 Before 2006 2006-2007 2007-2008 2008-2009 2009-2010 2010-2011 2011-2012 (Expected) ANDA's Filed Cumulative
Slide 20: R&D DMFs
R & D DMF’S 80 70 68 60 53 DMF filings 53 50 40 39 28 30 17 20 14 15 11 11 11 10 6 6 0 2006-2007 2007-2008 2008-2009 2009-2010 2010-2011 2011-2012 (Expected) DMF's filed Cumulative
Slide 21: Contract Manufacturing
CONTRACT MANUFACTURING • Alembic partners Multinational and Innovator Companies • Respecting customer IPR’s. • Lean and competitive structure – Vertical integration in R&D and manufacturing of intermediates, API’s and dosage forms. • Number of alliances already in place.
Slide 22: Research & Development
RESEARCH & DEVELOPMENT
Slide 23: Research & Development: R&D spend as % of sales
RESEARCH & DEVELOPMENT RESEARCH & DEVELOPMENT 5.00% 4.51% 4.50% 4.22% 4.30% 4.01% 4.06% 4.00% 3.60% 3.50% 3.00% 2.50% 2.00% 1.50% 1.00% 0.50% 0.00% 2005-06 2006-07 2007-08 2008-09 2009-10 2010-11 R&D spend as % to sales Increased thrust on research to create intellectual property
Slide 24: Research & Development
RESEARCH & DEVELOPMENT API Research • Participate in business strategy by developing non-infringing technologies Formulations Research • Expertise to develop tablets, pellets, capsules, liquids, semisolids and powders • Focus on Drug Delivery Research in the area of Oral–controlled release systems C
Slide 25: Financials
FINANCIALS
Slide 26: Sales [Rs. Million]
SALES [Rs. Million] 14000 12000 10000 8000 6000 4000 2000 0 '06-07 '07-08 '08-09 '09-10 '10-11 Year Demerged Gross Sales
Slide 27: PBIDTA [Rs. Million]
PBIDTA [Rs. Million] 1800 1600 1400 1200 1000 800 600 400 200 0 '06-07 '07-08 '08-09 '09-10 '10-11 Year Demerged PBIDTA
Slide 28: Financial Highlights – Sales – 2010-11
FINANCIAL HIGHLIGHTS – SALES – 2010-11 Rs. Lacs Sales Actual Actual Business Growth FY 10-11 FY 09-10 Share 11 % Formulation - Branded Business 59,842 49,661 50% 21% - Generic & NSA 9,502 8,829 8% 8% - Export 5,015 4,576 4% 10% Total 74,359 63,066 62% 18% International Division - API Domestic 9,451
Slide 29: Result Highlights – Q4 / FY-11
RESULT HIGHLIGHTS – Q4 / FY-11 Rs. Lacs Particulars Q4 Year 2011 2011 PBIDTA 2,722 16,033 PBT 1,303 10,685 PAT 1,028 8,539
Slide 30: Thank You
THANK YOU
Alembic Pharmaceuticals — Q4 FY2011 Earnings Presentation on 6ix